Jacob Holmes, Daria Torodii, Martins Balodis, Manuel Cordova, Albert Hofstetter, Federico Paruzzo, Sten O. Nilsson Lill, Emma Eriksson, Pierrick Berruyer, Bruno Simões de Almeida, Michael J. Quayle, Stefan Tommy Norberg, Anna Svensk-Ankarberg, Staffan Schantz, Lyndon Emsley
{"title":"通过核磁共振晶体学研究无定形药物阿托利夫拉朋的原子级结构","authors":"Jacob Holmes, Daria Torodii, Martins Balodis, Manuel Cordova, Albert Hofstetter, Federico Paruzzo, Sten O. Nilsson Lill, Emma Eriksson, Pierrick Berruyer, Bruno Simões de Almeida, Michael J. Quayle, Stefan Tommy Norberg, Anna Svensk-Ankarberg, Staffan Schantz, Lyndon Emsley","doi":"10.1039/d4fd00078a","DOIUrl":null,"url":null,"abstract":"We determine the complete atomic-level structure of the amorphous form of the drug altuliflapon, a 5-lipooxygenase activating protein (FLAP) inhibitor, by chemical shift driven NMR crystallography. The ensemble of preferred structures allows us to identify a number of specific conformations and interactions that stabilize the amorphous structure. These include preferred hydrogen bonding motifs with water and with other drug molecules, as well as conformations of the cyclohexane and pyrazole rings that stabilize structure by indirectly allowing for optimization of hydrogen bonding.","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Atomic-level structure of the amorphous drug Atuliflapon by NMR crystallography\",\"authors\":\"Jacob Holmes, Daria Torodii, Martins Balodis, Manuel Cordova, Albert Hofstetter, Federico Paruzzo, Sten O. Nilsson Lill, Emma Eriksson, Pierrick Berruyer, Bruno Simões de Almeida, Michael J. Quayle, Stefan Tommy Norberg, Anna Svensk-Ankarberg, Staffan Schantz, Lyndon Emsley\",\"doi\":\"10.1039/d4fd00078a\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We determine the complete atomic-level structure of the amorphous form of the drug altuliflapon, a 5-lipooxygenase activating protein (FLAP) inhibitor, by chemical shift driven NMR crystallography. The ensemble of preferred structures allows us to identify a number of specific conformations and interactions that stabilize the amorphous structure. These include preferred hydrogen bonding motifs with water and with other drug molecules, as well as conformations of the cyclohexane and pyrazole rings that stabilize structure by indirectly allowing for optimization of hydrogen bonding.\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://doi.org/10.1039/d4fd00078a\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1039/d4fd00078a","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
Atomic-level structure of the amorphous drug Atuliflapon by NMR crystallography
We determine the complete atomic-level structure of the amorphous form of the drug altuliflapon, a 5-lipooxygenase activating protein (FLAP) inhibitor, by chemical shift driven NMR crystallography. The ensemble of preferred structures allows us to identify a number of specific conformations and interactions that stabilize the amorphous structure. These include preferred hydrogen bonding motifs with water and with other drug molecules, as well as conformations of the cyclohexane and pyrazole rings that stabilize structure by indirectly allowing for optimization of hydrogen bonding.